Peginterferon alfa-2b
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | PegIntron | — | 2021-04-21 | europa.eu ↗ |
| Label expansions (7) | US (FDA) | PEGINTRON | — | 2001-08-07 – 2013-12-18 | fda.gov ↗ |
| Approved | US (FDA) | PEGINTRON | — | 2001-01-19 | fda.gov ↗ |
| Approved | EU (EMA) | PegIntron | — | 2000-05-24 | europa.eu ↗ |
Trials 187 · started per year
Also used as a comparator or background therapy in 82 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT01678131 Background | Oct 2012 → Aug 2013 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00630058 Background | Apr 2008 → Mar 2009 | chronic hepatitis C virus infection | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01081158 Background | Jul 2007 → Aug 2008 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00498979 Background | May 2007 → May 2010 | melanoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00398450 Background | Feb 2006 → Apr 2010 | cutaneous melanoma | University of California, San Diego | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00593151 Comparator | Jan → Dec 2008 | hepatitis C virus infection | Biolex Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 219 trials | ||||||
| Phase 2 | NCT04189276 Comparator | Dec 2019 → Jun 2021 | hepatitis B virus infection | Tasly Tianjin Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT02737046 Background | Dec 2016 → Dec 2024 | adult T-cell leukemia/lymphoma | University of Miami | Completed | No outcome recorded |
| Phase 2 | NCT01710501 Background | Dec 2012 → Nov 2013 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT01440595 Background | Nov 2011 → May 2012 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT01353911 Background | Jun 2011 → Jan 2013 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT01335529 Background | May 2011 → May 2014 | HIV infectious disease, hepatitis C virus infection | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 2 | NCT01016912 Background | Dec 2009 → Sep 2010 | chronic hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00959699 Comparator | Nov 2009 → May 2012 | HIV infectious disease, hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00919633 Comparator | Jun 2009 → Jul 2012 | hepatitis C virus infection | Medtronic Corporate Technologies and New Ventures | Completed | No outcome recorded |
| Phase 2 | NCT00863239 Comparator | Mar 2009 → Nov 2010 | chronic hepatitis C virus infection | Biolex Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00797745 Background | Nov 2008 → Jul 2009 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00528528 Background | Oct 2007 → Jul 2009 | chronic hepatitis C virus infection | Tibotec BVBA | Completed | No outcome recorded |
| Phase 2 | NCT00423670 Background | Jan 2007 → Aug 2008 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00367887 Comparator | Oct 2006 → Jul 2008 | hepatitis C virus infection | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00332176 Comparator | Jun 2006 → Dec 2008 | chronic hepatitis C virus infection | BioWest Therapeutics Inc | Unknown | No outcome recorded |
| Phase 2 | NCT00277238 Background | Feb 2006 → Jul 2007 | chronic hepatitis C virus infection | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00418054 Background | Dec 2005 → Jul 2006 | chronic hepatitis C virus infection | Romark Laboratories L.C. | Completed | No outcome recorded |
| Phase 2 | NCT00160251 Background | Sep 2005 → Jul 2007 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00148837 Background | Sep 2004 → Dec 2008 | chronic hepatitis C virus infection | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT01740089 Comparator | Nov 2011 → Jul 2012 | hepatitis C virus infection | Biocad | Completed | No outcome recorded |
| Phase 2/3 | NCT00689390 Background | Feb 2007 → Oct 2014 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 336 trials | ||||||
| Phase 3 | NCT07282249 Comparator | Dec 2025 → Apr 2027 expected | chronic hepatitis B virus infection | Grand Theravac Life Sciences (Nanjing) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06079879 Comparator | Dec 2023 → Jul 2027 expected | essential thrombocythemia | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04382937 Comparator | Jan 2016 → Jul 2020 | chronic hepatitis C virus infection | PharmaEssentia | Completed | No outcome recorded |
| Phase 3 | NCT02506153 Comparator | Nov 2015 → Sep 2023 overdue | cutaneous melanoma, mucosal melanoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02204475 Comparator | Nov 2014 → Jun 2016 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 3 | NCT03833362 Background | May 2014 → Mar 2016 | chronic hepatitis C virus infection | R-Pharm | Completed | No outcome recorded |
| Phase 3 | NCT01641666 Background | May 2014 → Sep 2016 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 3 | NCT02099604 Background | Apr 2014 | chronic hepatitis C virus infection | ANRS, Emerging Infectious Diseases | Withdrawn | No outcome recorded |
| Phase 3 | NCT01653236 Background | Dec 2013 → Dec 2015 | chronic hepatitis C virus infection | Theodor Bilharz Research Institute | Unknown | No outcome recorded |
| Phase 3 | NCT02103439 Comparator | Jun 2013 → Aug 2015 | hepatitis C virus infection | Biocad | Completed | No outcome recorded |
| Phase 3 | NCT01718301 Background | Mar 2013 → Mar 2015 | HIV infectious disease, chronic hepatitis C virus infection, coinfection | Anna Cruceta | Terminated | No outcome recorded |
| Phase 3 | NCT01718145 Comparator | Nov 2012 → Dec 2013 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01466192 Background | May 2012 → Aug 2013 | chronic hepatitis C virus infection | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01482767 Background | Apr 2012 → Apr 2015 | HIV infectious disease, hepatitis C virus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT01387763 Comparator | Jan 2012 → Jun 2020 | acquired polycythemia vera, essential thrombocythemia, primary myelofibrosis | Thomas Stauffer Larsen | Completed | No outcome recorded |
| Phase 3 | NCT01425203 Background | Nov 2011 → Oct 2013 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01457937 Background | Nov 2011 → Dec 2013 | chronic hepatitis C virus infection | University of Modena and Reggio Emilia | Unknown | No outcome recorded |
| Phase 3 | NCT01468584 Background | Nov 2011 → Sep 2013 | chronic hepatitis C virus infection | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01390844 Background | Oct 2011 → Jun 2015 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01374308 Comparator | Jun 2011 → Jun 2013 | chronic hepatitis B virus infection | Clinical Research Organization, Dhaka, Bangladesh | Unknown | No outcome recorded |
| Phase 3 | NCT01366638 Background | May 2011 → Nov 2012 | chronic hepatitis C virus infection | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 3 | NCT01290679 Background | Mar 2011 → Feb 2013 | hepatitis C virus infection | Janssen R&D Ireland | Completed | No outcome recorded |
| Phase 3 | NCT01095445 Comparator | Feb 2010 → Jun 2011 | chronic hepatitis C virus infection | University Health Network, Toronto | Terminated | No outcome recorded |
| Phase 3 | NCT01023035 Background | Dec 2009 → Oct 2011 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00910624 Background | Jun 2009 → Dec 2012 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00781274 Background | Dec 2008 → Jul 2010 | chronic hepatitis C virus infection | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00780416 Background | Nov 2008 → Aug 2010 | hepatitis C virus infection | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00780910 Background | Nov 2008 → Oct 2010 | chronic hepatitis C virus infection | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00708500 Background | Aug 2008 → Apr 2010 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00705432 Background | Aug 2008 → May 2010 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00237484 Background | Jul 2005 → Jun 2011 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00265395 Comparator | Dec 2004 → May 2008 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00230958 Background | Dec 2003 → Jan 2006 | chronic hepatitis C virus infection | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00248339 Comparator | May 2002 → Jul 2005 | hepatitis C virus infection | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 3 | NCT00122629 Background | Oct 2000 → May 2003 | chronic hepatitis C virus infection | French National Agency for Research on AIDS and Viral Hepatitis | Terminated | No outcome recorded |
| Phase 3 | NCT00299936 Background | — | chronic hepatitis C virus infection | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 416 trials | ||||||
| Phase 4 | NCT06900166 Comparator | Apr 2025 → Apr 2029 expected | chronic hepatitis B virus infection | Huashan Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT01770223 Background | Jan 2014 → Dec 2015 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 4 | NCT02168361 Comparator | Dec 2013 → Dec 2014 | chronic hepatitis C virus infection | Center For Hepatitis C, Atlanta, GA | Completed | No outcome recorded |
| Phase 4 | NCT01756079 Background | Feb 2013 → Nov 2015 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT01532843 Comparator | Jun 2012 → Aug 2015 | chronic hepatitis B virus infection | Foundation for Liver Research | Completed | No outcome recorded |
| Phase 4 | NCT01443923 Comparator | Sep 2011 → Sep 2013 | HIV infectious disease, hepatitis | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 4 | NCT01285050 Background | Jan 2011 → Apr 2015 | HIV infectious disease, hepatitis C virus infection | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT00993122 Comparator | Oct 2009 → Apr 2010 | hepatitis C virus infection | University of Roma La Sapienza | Completed | No outcome recorded |
| Phase 4 | NCT00803309 Comparator | Nov 2008 → Aug 2013 | chronic hepatitis C virus infection | HepNet Study House, German Liverfoundation | Terminated | No outcome recorded |
| Phase 4 | NCT00502099 Comparator | Jan 2006 → May 2009 | hepatitis C virus infection | Amr Hafez | Completed | No outcome recorded |
| Phase 4 | NCT01195181 Comparator | Sep 2005 → Dec 2009 | chronic hepatitis C virus infection | Azienda Ospedaliera di Padova | Completed | No outcome recorded |
| Phase 4 | NCT00202839 Comparator | Mar 2005 → Jul 2008 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00087607 Comparator | Jan 2004 → Mar 2006 | chronic hepatitis C virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00277862 Comparator | Apr 2002 → Mar 2007 | chronic hepatitis C virus infection | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT00207363 Comparator | Feb 2002 → Jan 2010 | chronic hepatitis C virus infection | Brooke Army Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00179413 Comparator | Jan 2000 → Dec 2009 | cirrhosis of liver, fibrotic liver disease, hepatitis C virus infection | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT06357806 Comparator | May 2024 → Oct 2026 expected | chronic hepatitis B virus infection | Beijing 302 Hospital | Active not recruiting | No outcome recorded |
| — | NCT03920605 Comparator | Feb 2019 → Oct 2021 | fibrotic liver disease, hepatitis B virus infection | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT01243281 Comparator | Mar 2011 → May 2013 | chronic hepatitis B virus infection | Chulalongkorn University | Unknown | No outcome recorded |
Press releases naming this drug 10 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-06-06 | Gilead Sciences | Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA gilead.com ↗ |
| 2017-10-28 | Novartis Pharmaceuticals | Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a novartis.com ↗ |
| 2015-07-24 | AbbVie | TECHNIVIE™ (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA Approval as the First and Only All-Oral, Interferon-Free Treatment for Genotype 4 Chronic Hepatitis C in the U.S. abbvie.com ↗ |
| 2015-04-24 | AbbVie | U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C abbvie.com ↗ |
| 2012-02-23 | Vertex Pharmaceuticals Incorporated | Vertex Announces 12-Week On-Treatment Data and SVR4 From Phase 2 Study of Interferon-Free (All-Oral) Treatment Regimen of INCIVEK®, VX-222 and Ribavirin in People with Genotype 1 Hepatitis C vrtx.com ↗ |
| 2011-03-31 | Vertex Pharmaceuticals Incorporated | Interim Phase 2 Data Showed Rapid Viral Response to VX-222 in Combination with Telaprevir, Pegylated-Interferon and Ribavirin Among People With Hepatitis C vrtx.com ↗ |
| 2008-04-24 | Vertex Pharmaceuticals Incorporated | Vertex Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin Treatment vrtx.com ↗ |
| 2006-05-21 | Vertex Pharmaceuticals Incorporated | Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients vrtx.com ↗ |
| 2006-04-29 | Vertex Pharmaceuticals Incorporated | Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients vrtx.com ↗ |
| 2006-01-09 | Vertex Pharmaceuticals Incorporated | VX-950, Investigational Oral Hepatitis C Protease Inhibitor, Demonstrates Rapid and Dramatic Reduction in Viral Levels in Combination with Pegylated Interferon vrtx.com ↗ |
Evidence & citations 47 cited values
Every value below carries the sentence it was read from. 289 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | peginterferon alfa-2b | “This is a study to evaluate the safety and tolerability of peginterferon alfa-2b (PegIFN alfa-2b) as adjuvant treatment in Japanese participants with malignant melanoma after...” NCT01636960 ↗110“Patients with mild hepatitis C recurrence (fibrosis stage F0 to F2, n = 54) were randomized to no treatment (group A, n = 27) or peginterferon alfa-2b/ribavirin for 48 weeks...” PMID 17484872 ↗ Mar 2007 “Lowering Viral Load With Nucleos(t)Ide Analogues Prior to Peginterferon Alfa-2b Treatment to Increase Sustained Response in HBeAg-positive Chronic Hepatitis B - a Pilot Study” NCT00883844 ↗ “This is a Phase 3b/4, prospective, open-label, randomized, multicenter study of peginterferon alfa-2b plus ribavirin in participants with chronic hepatitis C, genotype 1.” NCT00493805 ↗ “Peginterferon Alfa-2b Combined With Tenofovir Alafenamide Improves the Functional Cure Rate in Patients With HBeAg Negative Chronic Hepatitis B” NCT05490836 ↗ “PegIntron (peginterferon alfa-2b) administered at a dose of 1.5 mcg/kg subcutaneously (SC) once a week (QW) for up to 48 weeks” NCT00039871 ↗ “A Parallel Phase I/II Study of Low Dose Decitabine (5-Aza-Deoxycytidine) With Peginterferon Alfa-2b in Advanced Melanoma” NCT00791271 ↗ “Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: a randomized trial.” PMID 25200354 ↗ Aug 2014 “Peginterferon alfa-2b administered once as part of a pharmacokinetic study before and after anti-HIV medications.” NCT01285050 ↗ “Peginterferon Alfa-2A 180 micrograms/week or Peginterferon Alfa-2B 180 micrograms/week, for at most 96 weeks.” NCT03801538 ↗ “peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.” NCT02908763 ↗ “peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.” NCT02893124 ↗ “peginterferon alfa-2b at 1,5 ug/kg/week (standard dose) or at 1,0 ug/kg/week (lower dose)(preempt pen, sc)” NCT01195181 ↗ “Peginterferon alfa-2b (40KD, Y shape, the followings will refer as Ypeginterferon alfa-2b for short)” NCT01581398 ↗ “peginterferon alfa-2b 80 micrograms/week or peginterferon alfa-2a 180 micrograms/week” NCT02745704 ↗ “A Phase I Trial of Peginterferon Alfa-2b (PEG-Intron) for Plexiform Neurofibromas” NCT00253474 ↗ “This randomized trial assesses the efficacy and safety of peginterferon alfa-2b.” NCT00241618 ↗ “Peg-interferon alfa-2b at a dose of 1.5 mcg per kilogram of body weight weekly” NCT01121705 ↗ “PEG-Intron (peginterferon alfa-2b (PEGIFN)) Redipen” NCT00135798 ↗ “PegIntron (peginterferon alfa-2b; SCH 54031)” NCT00081770 ↗ “PegIntron (peginterferon alfa-2b; SCH 54031)” NCT00811967 ↗ “Sylatron(R) (Peginterferon alfa-2b)” NCT02948426 ↗ “Drug: Peg interferon alfa-2b” NCT02634294 ↗ |
| Known as | IFN-α-2b | “Patients were randomly assigned to treatment with octreotide LAR 20 mg every 21 days with either bevacizumab 15 mg/kg every 21 days or 5 million units of IFN-α-2b three times per week.” PMID 28384065 ↗ Apr 2017 |
| Known as | Interferon | “Interferon(PegIFN-α-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks” NCT04254874 ↗ |
| Known as | P-IFN alfa 2b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02112630 ↗ |
| Known as | PEG | “Arm 1A: PegIntron (PEG) + Ribavirin (RBV)” NCT00160251 ↗1“Peginterferon alfa-2b (PEG)” NCT01390844 ↗ |
| Known as | PEG (pegylated)-Intron | “The drug used in this study is PEG (pegylated)-Intron.” NCT00396019 ↗ |
| Known as | PEG IFN alfa 2b : Peg Intron | “PEG IFN alfa 2b : Peg Intron” NCT01457937 ↗ |
| Known as | PEG IFN-α | “Patients receive PEG-interferon alfa-2b (PEG IFN-α) subcutaneously (SC) on days 1, 8, 15, and 22.” NCT00085384 ↗ |
| Known as | Peg interferon alfa 2b (Peg Intron) | “Peg interferon alfa 2b (Peg Intron)” NCT00207363 ↗ |
| Known as | Peg-alpha interferon | “Peg-alpha interferon (Peg-Intron)” NCT00050531 ↗ |
| Known as | PEG-IFN | “We assigned 40 newly diagnosed chronic-phase CML patients to receive DAS 100 mg o.d. followed by addition of pegylated interferon-α2b (PegIFN) after 3 months (M3).” PMID 27133821 ↗ May 20168“peginterferon alfa-2b (PEG-IFN) and ribavirin (RBV) for difficult-to-treat patients” PMID 22239511 ↗ Nov 2011 “versus pegylated interferon (Peg-IFN) in naïve chronic hepatitis B patients.” PMID 30133478 ↗ Aug 2018 “Peg-Interferon (PegIFN) alfa 2b by subcutaneous injection 1,5 µg/kg/week” NCT01335529 ↗ “PEG-Intron (peginterferon alfa-2b (PEGIFN)) Redipen” NCT00135798 ↗ “peginterferon alfa-2b (PEG-IFN) subcutaneously” NCT00687544 ↗ “Pegylated-Interferon Alfa 2b (PEG-IFN)” NCT01482767 ↗ “Peginterferon alfa-2b (Peg-IFN)” NCT01440595 ↗ “peginterferon-α-2b (PEG IFN)” PMID 25196718 ↗ Nov 2014 |
| Known as | peg-IFN alfa-2b | “The findings from this study will aid in the understanding of whether HIV infection affects HCV antiviral and host responses to combination therapy using BOC/peg-IFN alfa-2b/RBV.” NCT01443923 ↗13“The control group received 48 subcutaneous injections of Peg-IFN alfa 2b, 180 μg per dose, every week, for 48 consecutive weeks.” PMID 30133478 ↗ Aug 2018 “This study will use a new, longer acting form of IFN called PEG-IFN alfa-2b.” NCT00015652 ↗ “PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day)” NCT01457937 ↗ “Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV)” NCT01606800 ↗ “Pegylated interferon (PEG-IFN) alfa-2b plus ribavirin (RBV)” PMID 20189674 ↗ Feb 2010 “Peginterferon alfa-2b (pegIFN alfa-2b)” NCT01366638 ↗ |
| Known as | PEG-IFN-alpha-2b | “Participants who have chronic hepatitis C genotype 1 monoinfection (N=50) or coinfection with HIV-1 (N=50), and who are na(SqrRoot) ve to IFN-based HCV treatment, will receive...” NCT01443923 ↗7“This is an exploratory study and is a Phase 3, single-arm, multi-center, open-label study of pegylated interferon alfa-2b, PEG-IFN alpha-2b (PEG-Intron) and ribavirin (RBV) to...” NCT00378599 ↗ “To characterize the ocular changes associated with peginterferon alpha 2b (peg-IFN alpha-2b) and ribavirin therapy for chronic hepatitis C infection in HIV co-infected individuals.” PMID 15316341 ↗ Sep 2004 “The EORTC 18991 trial assessed the effect of long-term adjuvant pegylated interferon (Peg-IFN) alpha-2b administered weekly in patients with lymph node-positive melanoma.” PMID 19621225 ↗ Jul 2009 “to receive PEG-IFN alpha-2b (1.5 microgram/kg/week) plus entecavir (0.5 mg/day) or PEG-IFN alpha-2b (1.5 microgram/kg/week) alone for 48 weeks” NCT01243281 ↗ “1.5 μg/kg weekly dose of subcutaneous PEG-IFN alpha-2b (PegIntron A, Schering-Plough, Osaka, Japan)” NCT00956982 ↗ “Peg-IFN alpha-2b monotherapy (1.5 μg/kg/week) for 24 or 12 weeks” PMID 24442928 ↗ Apr 2014 |
| Known as | Peg-IFN-α-2β | “peginterferon alfa-2β (Peg-IFN-α-2β) combined with nucleos(t)ide analogues (NAs)” NCT07553767 ↗ |
| Known as | peg-IFN2b | “In this study we sought to characterize the relationship between several pharmacokinetic and pharmacodynamic parameters and virologic responses among HIV/hepatitis C virus...” PMID 19898214 ↗ Nov 2009 |
| Known as | PEG-INF | “Participants who achieved RVR after 4 weeks of PEG-INF alfa-2b plus RBV treatment were randomized to receive either 20 or 44 weeks of continued therapy, for a total of 24 or 48...” NCT01606800 ↗ |
| Known as | PEG-INF alfa-2b | “Participants who achieved RVR after 4 weeks of PEG-INF alfa-2b plus RBV treatment were randomized to receive either 20 or 44 weeks of continued therapy, for a total of 24 or 48...” NCT01606800 ↗ |
| Known as | PEG-Interferon a-2b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00215891 ↗ |
| Known as | PEG-interferon-α | “weekly subcutaneous PEG-interferon-α (PEG-Intron)” NCT00886457 ↗ |
| Known as | PEG2b | “peginterferon alfa-2b (PEG2b) (SCH 54031)” NCT00104052 ↗1“Peginterferon alfa-2b (PEG2b)” NCT01023035 ↗ |
| Known as | PegIFNa2b | “Peginterferon-alpha 2b (PegIFNa2b);” NCT00585221 ↗ |
| Known as | PegIFNα-2b | “This randomized, prospective, parallel-group clinical trial compared the efficacy and safety of pegylated interferon α-2a (PEG-IFN α-2a) plus ribavirin and PEG-IFN α-2b plus...” PMID 21281434 ↗ Jan 201124“In the pilot NCT01935089 trial, we tested whether pegylated interferon alpha2b (Peg-IFN-α2b) with antiretroviral therapy (ART) was safe and could impact HIV and immune measures...” PMID 33323024 ↗ Jan 2021 “Therefore, this study aims to conduct a prospective cohort study to compare the therapeutic effects of pegylated interferon α-2b (Peg IFNα-2b) combined with nucleos(t)ide...” NCT07071636 ↗ “Participants in NAs+Peg IFN Group will be treated by Peg IFNα-2b （180ug per week, the dose will be changed to 135ug or 90ug per week during the treatment if patients could not...” NCT03969017 ↗ “EPIC(3) included a prospective trial assessing long-term peginterferon alfa-2b (PegIFNα-2b) maintenance therapy in patients with METAVIR fibrosis scores (MFS) of F2 or F3 who...” PMID 23159770 ↗ Nov 2012 “In the adjuvant setting for malignant melanoma, interferon (IFN)-α-2b and pegylated (PEG) IFN-α-2b were approved in several countries including the USA before these were...” PMID 27087489 ↗ Oct 2016 “In this open-label pilot study, 29 patients with CHC who failed previous therapy with (peg)IFNα/ribavirin were treated with SAMe, betaine, pegIFNα2b and ribavirin.” PMID 21079746 ↗ Nov 2010 “The pegylated interferon (Peg-IFN) group will receive ETV for the first 48 weeks, followed by combination therapy with Peg-IFN α-2b for the remaining 48 weeks” NCT07345624 ↗ “Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-α-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks” NCT04254874 ↗ “Pegylated interferon α-2b (PegIFNα-2b) therapy can help inactive hepatitis B surface antigen (HBsAg) carriers (IHCs) achieve clinical cure.” PMID 37577817 ↗ Aug 2023 “Pegylated Interferon alpha 2b (peg-IFN-α2b) will be administered weekly via subcutaneous route.” NCT03588715 ↗ “dasatinib combined to Peg-IFN-α2b (Dasa-PegIFN, NCT01872442)” PMID 36214090 ↗ Oct 2022 “Group B received PegIFNα-2b monotherapy for 48 weeks” NCT06900166 ↗ “Peginterferon Alfa (PegIFN α)-2b/Ribavirin (Riba)” NCT01457937 ↗ “pegylated interferon α-2b (Peg-IFN-α2b)” NCT07183293 ↗ |
| Known as | PegIFNα-2b (PegIntron) | “PegIFNα-2b (PegIntron)” NCT01290679 ↗ |
| Known as | peginterferon | “RATIONALE: Peginterferon (PEG-interferon) alfa-2b may stop the growth of cancer by stopping blood flow to the tumor.” NCT00049530 ↗1“Peginterferon alpha-2b 1.5 μg/kg per week s.c.for 48 weeks” NCT01532843 ↗ |
| Known as | Peginterferon Alfa (PegIFN α)-2b | “Peginterferon Alfa (PegIFN α)-2b/Ribavirin (Riba)” NCT01457937 ↗ |
| Known as | Peginterferon Alpha-2b | “We conducted a randomized controlled trial of CHB patients on NA >12 months with HBV DNA(-) randomized to switch or add-on peginterferon-alpha2b (1.5 μg/kg/weekly) for 48 weeks...” PMID 33895361 ↗ Apr 202116“Peg-interferon alpha 2-b (a subcutaneous injection of 1.5 micrograms/kg once a week)” NCT02247440 ↗ “With Peg-Interferon alpha2b and Ribavirin in Patients With Genotype 3 Chronic HCV” NCT01121705 ↗ “Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV)” NCT01606800 ↗ “Peginterferon alpha-2b 1.5 μg/kg per week s.c.for 48 weeks” NCT01532843 ↗ “Peg Interferon Alpha 2b (Peg Intron)” NCT00303290 ↗ |
| Known as | Peginterferon α-2b | “This trial is a part of ZhuFeng Project (The Clinical Cure Project of Chronic Hepatitis B in China; ClinicalTrials.gov, identifier: NCT04035837) and a part of E-Cure Study...” PMID 40390028 ↗ May 20251“peginterferon-α-2b (PEG IFN)” PMID 25196718 ↗ Nov 2014 |
| Known as | Peginterferon α-2b (PEG) | “Peginterferon α-2b (PEG), 1.5 μg/kg, will be administered weekly by subcutaneous injection for the specified period of time (see Study Design, Arms A and B). Pegintron® (MSD...” NCT01928511 ↗ |
| Known as | PegIntron | “This is a Phase 3b, randomized, open-label, parallel-group, multi-center, multi-national study of low-dose maintenance Peg interferon alpha-2b (Peg-Intron®) in subjects with...” NCT00381017 ↗52“Peginterferon α-2b (PEG), 1.5 μg/kg, will be administered weekly by subcutaneous injection for the specified period of time (see Study Design, Arms A and B). Pegintron® (MSD...” NCT01928511 ↗ “This study will investigate the intracellular exposure to active ZDV metabolites prior to and after treatment with Rebetron or treatment with PEG-Intron (pegylated interferon)...” NCT00059358 ↗ “Recently a new formulation of Interpheron alpha2b is available. Conjugated with polietilenglicol (Pegintron) that need only one dose weekly and has not been tested in MM.” NCT01325896 ↗ “each dosage schedule with or without the co-administration of pegylated interferon-α (Pegintron 1 μg/kg s.c.) at the day of vaccine administration” NCT01923116 ↗ “Phase II Study of Weekly Administered High-Dose Pegylated Interferon Alfa-2B (PEGIntron) in Advanced Stage Low Grade Non-Hodgkin's Lymphoma” NCT00006039 ↗ “Phase II Trial of ZD1839 (IRESSA®) and Pegylated Interferon Alfa 2b (PEG-Intron™) in Unresectable or Metastatic Renal Cell Carcinoma” NCT00467077 ↗ “Patients receive peginterferon alfa-2b (Pegintron®) combined with first-line nucleos(t)ide analogues (TDF/TAF/TMF)” NCT07553767 ↗ “Peginterferon alfa-2b (12 kD) [PEG-Intron] at a dosage of 1.5 μg/kg SC once weekly” NCT00087607 ↗ “A Phase I Trial of Peginterferon Alfa-2b (PEG-Intron) for Plexiform Neurofibromas” NCT00253474 ↗ “Escalating Doses of Sub-Q Pegylated (PEG) Interferon-alfa 2B (PEG-Intron)” NCT00886457 ↗ “Induction PEG-Interferon alfa-2b (PEG-Intron) and Ribavirin (Rebetol)” NCT00207363 ↗ “Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)” NCT00511121 ↗ “PEG-Intron (peginterferon alfa-2b (PEGIFN)) Redipen” NCT00135798 ↗ “Peginterferon alfa-2b (PegIntron, SCH 54031)” NCT00686790 ↗ “Pegylated Interferon-Alfa 2b (PEG Intron)” NCT00861406 ↗ “Pegylated interferon alfa-2b (PegIntron)” NCT00371761 ↗ “Peg Interferon Alpha 2b (Peg Intron)” NCT00303290 ↗ “Peginterferon-alpha-2b (PEG-Intron)” NCT00248339 ↗ “PEG-Intron (peginterferon alfa-2b)” NCT00049842 ↗ “peginterferon-alfa 2b (PegIntron)” NCT00423670 ↗ “Peg-IFN alfa2b (PegIntron)” NCT00528528 ↗ |
| Known as | PegIntron A | “1.5 μg/kg weekly dose of subcutaneous PEG-IFN alpha-2b (PegIntron A, Schering-Plough, Osaka, Japan)” NCT00956982 ↗ |
| Known as | Pegylated IFN-alpha 2b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02447887 ↗ |
| Known as | pegylated IFNa2b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00593151 ↗ |
| Known as | pegylated interferon (Peg IFN)α-2b | “pegylated interferon (Peg IFN)α-2b” NCT03969017 ↗ |
| Known as | Pegylated Interferon Alfa-2b | “Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life...” PMID 19433686 ↗ May 200932“An Open-Label, Single-arm, Multicenter Phase I Study of SCH 54031 (Pegylated Interferon Alfa-2b) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (Protocol...” NCT01636960 ↗ “Phase II Study of Weekly Administered High-Dose Pegylated Interferon Alfa-2B (PEGIntron) in Advanced Stage Low Grade Non-Hodgkin's Lymphoma” NCT00006039 ↗ “patients receive ribavirin (10,4 mg/kg/day) and pegylated interferon alfa-2b (1,5 mcg/kg/week).” NCT00993122 ↗ “Pegylated interferon alfa-2b administered subcutaneously 1.5 mcg/kg/week” NCT01606800 ↗ “Pegylated interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 24wks” NCT00277238 ↗ “Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks” NCT00142103 ↗ |
| Known as | Pegylated Interferon Alpha-2b | “The purpose of this study is to determine if treatment with pegylated interferon alpha 2b (peg-IFN-α2b) will reduce the amount of integrated HIV DNA in peripheral blood cells...” NCT02227277 ↗26“In this study we sought to characterize the relationship between several pharmacokinetic and pharmacodynamic parameters and virologic responses among HIV/hepatitis C virus...” PMID 19898214 ↗ Nov 2009 “In the pilot NCT01935089 trial, we tested whether pegylated interferon alpha2b (Peg-IFN-α2b) with antiretroviral therapy (ART) was safe and could impact HIV and immune measures...” PMID 33323024 ↗ Jan 2021 “Eligible patients were treated with pegylated interferon alpha-2b (Peg Intron®; Schering-Plough (Brinny) Company, Innishannon, County Cork, Ireland)” NCT02634294 ↗ “Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.” PMID 27087489 ↗ Oct 2016 “Pegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir in HBeAg-negative Chronic Hepatitis B” NCT01243281 ↗ “pegylated interferon alpha 2b 1.5 mg/kg/week sc plus weight-adjusted ribavirin po for 48 weeks.” NCT01529073 ↗ “plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week” NCT03483987 ↗ “Pegylated-Interferon-alpha2b (SylatronTM)” NCT01502696 ↗ |
| Known as | pegylated interferon α-2b | “Therefore, this study aims to conduct a prospective cohort study to compare the therapeutic effects of pegylated interferon α-2b (Peg IFNα-2b) combined with nucleos(t)ide...” NCT07071636 ↗13“We assigned 40 newly diagnosed chronic-phase CML patients to receive DAS 100 mg o.d. followed by addition of pegylated interferon-α2b (PegIFN) after 3 months (M3).” PMID 27133821 ↗ May 2016 “Pegylated interferon α-2b (PegIFNα-2b) therapy can help inactive hepatitis B surface antigen (HBsAg) carriers (IHCs) achieve clinical cure.” PMID 37577817 ↗ Aug 2023 “patients received PEGylated-interferonα2b (1.5 μg/kg/week)+ ribavirin (800-1400 mg/day) alone until W4 and with BOC(800 mgTID) until W48.” PMID 27077673 ↗ Feb 2016 “a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin” PMID 24442928 ↗ Apr 2014 “pegylated interferon α-2b (Peg-IFN-α2b)” NCT07183293 ↗ “Entecavir + Pegylated interferon α-2b” NCT07345624 ↗ |
| Known as | pegylated interferon-α | “each dosage schedule with or without the co-administration of pegylated interferon-α (Pegintron 1 μg/kg s.c.) at the day of vaccine administration” NCT01923116 ↗ |
| Known as | PGI | “Pegylated Interferon Alpha-2b (PGI)” NCT00525031 ↗ |
| Known as | Recombinant Interferon Alfa-2b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04379518 ↗ |
| Known as | SCH 054031 | “Peginterferon alfa-2b (SCH 054031)” NCT00724620 ↗1“Peginterferon alfa-2b (SCH 054031)” NCT00687544 ↗ |
| Known as | SCH 54031 | “An Open-Label, Single-arm, Multicenter Phase I Study of SCH 54031 (Pegylated Interferon Alfa-2b) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (Protocol...” NCT01636960 ↗7“Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With SCH54031 (PEG Interferon Alpha 2B/PEG Intron) and Low-Dose Cytosine Arabinoside (Ara-C)” NCT00303290 ↗ “Peginterferon alfa-2b (PegIntron, SCH 54031)” NCT00686790 ↗ “PegIntron (peginterferon alfa-2b; SCH 54031)” NCT00081770 ↗ “Pegylated interferon alfa-2b (SCH 54031)” NCT00708500 ↗ “peginterferon alfa-2b (SCH 54031)” NCT00049842 ↗ “peginterferon alfa-2b (SCH 54031)” NCT00048724 ↗ “Peginterferon alfa-2b (SCH 54031)” NCT00910624 ↗ |
| Known as | Sylatron | “To estimate the 1-year disease stabilization rate associated with the use of Sylatron (peginterferon alfa-2b) in patients with progressive unresectable or recurrent...” NCT01964300 ↗ |
| Known as | SylatronTM | “Pegylated-Interferon-alpha2b (SylatronTM)” NCT01502696 ↗ |
| Known as | Ypeginterferon alfa-2b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01143662 ↗ |
| Action | Inhibit | “Interferon-alfa inhibits HIV replication in vitro” NCT00006325 ↗ |
| Modality | Protein / enzyme biologic | “Biological: recombinant interferon alfa-2b” NCT00002556 ↗ |
| Route | Subcutaneous | “Given SC” NCT00002556 ↗ |